EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating
IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trialLONDON (BUSINESS WIRE) Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug.
IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042's ongoing phase 1/2 trial Ellipses Pharma ("Ellipses"), a global drug development company focused
In a milestone ruling, UK health chiefs have approved nivolumab for sufferers who are too frail to withstand treatments such as chemotherapy (file photo)